Genfit SA: Lead program Elafibranor is PPAR alpha/delta agonist in Ph 3 for NASH with data expected by YE 2019. Announced positive ph 2 PBC data in Dec 2018. Announced NASH biomarker diagnostic program; signed licensing agreement with LabCorp.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase III
Disease Space
Anti-inflammatory, Metabolic Disorders
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
500MM +
Therapeutic Modalities
Small Molecule
Website:
Address:
245, First Street, 18th Floor
Cambridge, MA 02142
United States

Company Participants at Genfit EASL KOL Event Vienna 2019

  • Jean-Francois Mouney, CEO

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout Clients at Jefferies

New York, NY, United States, June 4 – June 7, 2019

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.